AMGN vs DXCM
By Alex · Tickerpine
Amgen Inc. vs DexCom, Inc., side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | AMGN | DXCM |
|---|---|---|
| Price | $358.33 | $70.14 |
| Market cap | $193.39B | $27.07B |
| P/E ratio | 24.9 | 30.1 |
| ROE | 101.32% | 35.62% |
| Profit margin | 20.96% | 19.31% |
| Revenue growth | 5.80% | 15.00% |
| Dividend yield | 2.81% | — |
| Beta | 0.42 | 1.44 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
AMGN vs DXCM in plain English
- AMGN is the bigger company — about 7.1× the market cap of DXCM.
- AMGN is cheaper on earnings (P/E 24.9 vs 30.1).
- AMGN earns a higher return on equity (101% vs 36%).
- DXCM is growing revenue faster (15% vs 6%).
- AMGN pays a dividend (2.81%) while the other effectively doesn't.
How would $1,000 have done in each?
AMGN return calculator
See what $1,000 in Amgen Inc. would be worth today.
DXCM return calculator
See what $1,000 in DexCom, Inc. would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.